Executive board changes at Germany's Merck

28 September 2020

Germany’s Merck KGaA (MRK: DE) today announced that next year Dr Stefan Oschmann, chairman of the firm’s executive board of Merck, will hand over the position to Dr Belén Garijo, who will also become chief executive on May 1, 2021.

She is currently vice chairman of the executive board and deputy CEO of Merck as well as CEO Healthcare. Dr Oschmann will leave the company as planned after 10 years on the executive board, five of them as chairman and CEO, to turn to other tasks.

“With Belén Garijo an internationally very experienced and highly recognized manager will take over the chair of the executive board of Merck. She knows our company extremely well and has done excellent work in transforming our Healthcare business sector. Belén Garijo and Stefan Oschmann have been collaborating closely and trustfully for many years. This will ensure a seamless transition and continuity in corporate management,” said Johannes Baillou, chairman of the board of partners of E Merck KG, also thanking Dr Oschmann “for an extremely successful tenure.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK